Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial.

Thumbnail
View/Open
Date
2019-12-05
ICR Author
Author
Hui, R
Pearson, A
Cortes Castan, J
Campbell, C
Poirot, C
Type
Journal Article
Metadata
Show full item record
URI
https://repository.icr.ac.uk/handle/internal/3386
DOI
Collections
Research team
Molecular Oncology
Language
eng
Date accepted
2019-10-09
License start date
2018-10
Citation
Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 29 Suppl 8 pp. viii93 - ?
Publisher
Elsevier BV